WO2003082918A1 - Vegf peptides and their use - Google Patents
Vegf peptides and their use Download PDFInfo
- Publication number
- WO2003082918A1 WO2003082918A1 PCT/GB2003/001375 GB0301375W WO03082918A1 WO 2003082918 A1 WO2003082918 A1 WO 2003082918A1 GB 0301375 W GB0301375 W GB 0301375W WO 03082918 A1 WO03082918 A1 WO 03082918A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fmoc
- vegf
- peptide
- peptides
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to peptides which are fragments of VEGF (vascular endothelial growth factor) and which have activity of potential benefit in therapy.
- VEGF vascular endothelial growth factor
- VEGF-A is a secreted polypeptide which is essential for formation of the vascular system in embryogenesis and plays a major role in angiogenesis in a variety of disease states.
- VEGF expression is upregulated by hypoxia and several cytokines in diverse cell types, and elicits multiple biological activities in vivo and in vitro, including the differentiation, proliferation, migration and survival of endothelial cells, increased vascular permeability, monocyte migration, and increased endothelial production of the vasodilatory factors NO and prostacyclin.
- VEGF-A exists in multiple isoforms, of 121 , 145, 165, 189 and 206 amino acids, generated by alternative mRNA splicing, of which VEGF 121 , VEGF 145 and VEGF 165 are known to be secreted and biologically active.
- Two distinct protein tyrosine kinase receptors for VEGF have been identified, i.e. Flt-1 (VEGFR1 ) and KDR/Flk-1 (VEGFR2).
- Flt-1 Flt-1
- VEGFR2 Two distinct protein tyrosine kinase receptors for VEGF have been identified, i.e. Flt-1 (VEGFR1 ) and KDR/Flk-1 (VEGFR2).
- KDR/flk-1 is thought to be the receptor which primarily mediates the mitogenic effects of VEGF in endothelial cells and angiogenesis in vivo; the function of Flt-1 in endothelial cells is unknown.
- NP-1 neuropilin-1
- VEGF neuropilin-1
- NP-1 neuropilin-1
- VEGF promotes the survival of tumour cells expressing NP-1 , including some breast carcinoma cells (Bachelder ef al, Cancer Res 61 : 5736-5740, 2001).
- the role of NP-1 in mediating biological effects of VEGF is still largely unknown.
- NP-1 is a receptor for a family of molecules called semaphorins or collapsins which play a key role in the guidance of neuronal axons during mammalian development.
- NP-1 is known to mediate the growth cone-collapsing and chemorepulsive activity of semaphorin 3.
- the shortest active peptide (SEQ ID NO. 1 ) is
- CSCKNTDSRCKARQLELNERTCRC i.e. VEGF (137-160), or amino acids 22-44 of exon 7 and amino acid 1 of exon 8.
- the terminal cysteine residue (C 137 in VEGF) is apparently essential for activity and the molecule's 3D structure. It is suggested that there may be intradisulfide bonding within the VEGF monomer. Summary of the Invention Surprisingly, it has been found that certain peptides have NP-1 antagonist activity.
- a novel peptide according to the present invention has SEQ ID NO. 2, i.e. the amino acid sequence
- SCKNTDSRCKARQLELNERTCRCDKPRR or a fragment thereof that substantially retains NP-1 antagonist activity, in cyclic form.
- the given sequence corresponds to amino acids 138 to 165 within VEGF, i.e. including part at least of exon 8. Surprisingly, activity has been found in peptides lacking the Cys residue indicated by Soker ef a/to be essential.
- the invention also encompasses variants of the given sequence, in which the novel activity, i.e. the NP-1 antagonism, is retained without unexpected structural variation.
- the given sequence may include isosteric or homologous replacements or derivatisations that render the peptide relatively stable.
- Peptides of the invention may be synthesised by known methods.
- a linear peptide may be produced by automated peptide synthesis, followed by cyclisation.
- Known cyclisation procedures include those described by Tarn et al, JACS 113:6657-62 (1991 ).
- Other cyclisations e.g. Mitsunobu or olefin metathesis ring closure, may also be used.
- a peptide of this invention preferably has 4 Cys residues. It is preferably bicyclic. As indicated above, peptides of the invention may include modifications of the given sequence. Such modifications are well known to those skilled in the art. Isosteric replacements include Abu for Cys (this may be desirable where the peptide should retain an even number of Cys residues for cyclisation), Phe for Tyr and different alkyl/aryl substituents. The shifting of substituents within an amino acid residue, from a C atom to a N atom, to produce peptoids having greater resistance to proteolysis, and other modifications, are known and are included within the scope of this invention. A specific peptide reported here is N-acetylated; other terminal modifications will also be known to those of ordinary skill in the art. Such modified peptides may act as prodrugs, and/or have modified immunogenicity.
- the NP-1 antagonist properties of a peptide of this invention may be determined by the procedure described below.
- the level of activity is preferably at least 25 or 50% as great as that for the bicyclic 28-mer that has been synthesised.
- peptides of the invention may be useful in the treatment of diseases in which NP-1 may have a significant role in pathology.
- peptides of the invention may be formulated and administered by procedures, and using components, known to those of ordinary skill in the art.
- the appropriate dosage of the peptide may be chosen by the skilled person having regard to the usual factors such as the condition of the subject to be treated, the potency of the compound, the route of administration etc. Suitable routes of administration include intramuscular, intranasal and subcutaneous.
- a NP-1 antagonist may compete with semaphorin 3 for binding to NP-1 , and thereby antagonise effects of semaphorin 3 on axonal outgrowth and migration in nerve cells.
- NP-1 antagonists may promote the survival of semaphorin 3-responsive neurones, an effect that would confirm or enhance its utility in the applications given above, and may extend these applications, e.g. to treating neuronal death caused by episodes of ischaemia as in stroke and some eye diseases.
- NP-1 plays an important role in angiogenesis and may be essential for VEGF-induced angiogenesis in cancer, eye disease, rheumatoid arthritis and other diseases. Therefore, NP-1 antagonists may have applications in the inhibition of VEGF-dependent angiogenesis in disease. NP-1 antagonists may also play a role in immunosuppression. Therefore, it may be useful to give a peptide of the invention before, during or after a transplant.
- a NP-1 antagonist may compete with VEGF for binding to NP- 1 in tumour cells and promote cell death in NP-1 -expressing tumour cells. Potential applications of this are in anti-cancer therapy.
- the following Examples illustrate the invention. Abbreviations
- MBHA methylbenzhydrylamine
- Fmoc 9-fluorenylmethoxy-carbonyl
- Ala alanine
- Arg arginine
- Asn asparagine
- Asp aspartic acid
- Abu aminobutyric acid
- Cys cysteine
- Gin glutamine
- Glu glumatic acid
- Gly glycine
- His histidine
- lie isoleucine; Leu, leucine; Lys, lysine; Met, methionine; Phe, phenylalanine
- Pro proline
- Ser, serine; Thr threonine
- Trp tryptophan
- Tyr tyrosine
- Val valine
- Pbf 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
- Pmc 2,2,5,7,8-pentamethylchroman-6-sulfonyl
- Trt trityl
- the peptides shown in Fig. 1 were synthesised on an automated AMS 422 Multiple Peptide Synthesiser using the solid phase approach.
- the Rink Amide MBHA resin (0.59 and 0.68 mmol/g loading) and the N-Fmoc strategy with orthogonal protection (Acm, t-Bu) of the Cys side chains of derivatives to be cyclised were applied.
- the desired peptide was synthesised on a 25 ⁇ M scale and coupled once with a basis coupling time of 30 minutes.
- the resin and the amino acid derivatives Fmoc-Ala-OH.H 2 0, Fmoc-Arg(Pbf/Pmc)-OH, Fmoc- Asn(Trt)-0H, Fmoc-Asp(OtBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-lle-OH, Fmoc- Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Phe-OH, Fmoc-Pro.H 2 0, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc
- Each amino acid was sequentially coupled to the growing peptide chain from the C- to the N-terminus, applying Pybop (Calbiochem-Novabiochem) and NMM (Rathburn Chemicals, Walkerburn, UK) as coupling reagents via the active ester method. Removal of the N-Fmoc protecting group was carried out with 20% piperidine in DMF (Rathburn Chemicals, Walkerburn, Scotland) followed by sequential washes with DMF and DCM. Automatic acetylation was carried out after the synthesis of each peptide with a 4-fold excess of acetic acid (0.7 molar, Rathburn Chemicals, Winterburn Scotland) based on the substitution of the Rink-Amide-MBHA resin.
- the coupling reagent, Pybop, NMM and all amino acid derivatives were dissolved in DMF (0.7 M, 4-fold excess based on the substitution of the Rink-Amide-MBHA-resin) except for the amino acids Fmoc- His(Trt)-OH and Fmoc-Phe-OH. These protected amino acid derivatives were dissolved in N-methylpyrrolidone. All solvents used were of HPLC-grade quality.
- the peptides were cleaved from the resin with simultaneous deprotection using 90% TFA at room temperature for 3 hours in the presence of 5% thioanisole, 2.5% water and 2.5% ethanedithiol as a scavenger of reactive cations generated.
- the cleavage mixture was filtered and precipitated in ice-cold TBME.
- the remaining resin was washed once with the cleavage reagent, filtered and combined with the previous fractions.
- the precipitates were collected after centrifugation, washed three times with ice-cold TBME and allowed to dry overnight at room temperature.
- the crude peptides were dissolved in 15% aqueous acetic acid and lyophilised for 2 days (-40° C, 6 mbar). Purification and Characterisation
- the crude peptides were analysed by analytical LC-MS on a Quattro LC Mass Spectrometer from Micromass with a Hewlett-Packard HPLC instrument, model 1100 using analytical reverse-phase columns (column Alltech Hypersil PEP reverse-phase column, 100 A, C 8 , 5 ⁇ (250 x 4.6 mm) 0% ⁇ 50% acetonitrile in 20 minutes. The separations were monitored at a wavelength of 215 nm for the amide bond absorbance with a flow rate of 1 mL/min. The crude peptides were purified by preparative reverse-phase HPLC (Gilson), monitored at 215 nm and eluted at a flow rate of 20 mL/min.
- the same mobile phase as stated for the LC-MS analysis of the crude peptides was used.
- the crude peptides were purified using an Alltech Hypersil PEP reverse-phase column, 100 A, C 8 , 8 ⁇ (250 x 22 mm). They were eluted with 0% ⁇ 50% acetonitrile in 20 minutes.
- the analogues were greater than 95% pure using high performance liquid chromatography (LC-MS) and had the expected amino acid analysis.
- SEQ ID NO. 2 was synthesised by an automated single solid-phase approach (Applied Biosystems 433A peptide synthesiser) using the Fmoc- Arg(Pbf)-p-alkoxybenzyl alcohol resin (0.59 mmol/g loading). Amino acids were attached by Fmoc strategy on a 0.25 mmol scale using FastmocTM chemistry with a single coupling time of 21 minutes.
- HBTU 2-(1H-benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium hexafluorophosphate
- DMF Applied Biosystems, Warrington, UK
- DIEA N,N-diisopropylethylamine
- Ac-SEQ ID NO. 2 was synthesized by an automated multiple solid-phase approach (Rainin Symphony multiple peptide synthesiser) using the Fmoc- Arg(Pbf)-p-alkoxybenzyl alcohol resin (0.59 mmol/g loading). Amino acids were attached by Fmoc strategy on a 0.2 mmol scale (peptides 3) using Fmoc chemistry with a single coupling time of 20 minutes.
- the resin and the amino acid derivatives Fmoc-Ala-OH, Fmoc-Abu-OH, Fmoc-Arg(Pbf)-OH, Fmoc- Asn(Trt)-OH, Fmoc-As ⁇ (OtBu)-OH, Fmoc-Cys(Trt)-OH (peptide 3 positions 9 and 23), Fmoc-Cys(Acm) (peptide 3 positions 2 and 21 ), Fmoc-Gln(Trt)-OH, Fmoc- Glu(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Pro-OH, Fmoc- Ser(tBu)-OH, Fmoc-Thr(tBu)-OH and Fmoc-Tyr(tBu)-OH were purchased from Bachem AG, Bubendorf, Switzerland.
- Each amino acid was added sequentially to the growing peptide chain from the C- to the N- termini applying 2-(1 H- benzotriazol-1-yl)-1 ,1 ,3,3-tetramethyluronium tetrafluoroborate (TBTU, Severn Biotech Ltd, Kidderminster, UK) and N,N-diisopropylethylamine (DIEA, Fisher Chemicals, Loughborough, UK) as coupling reagents. Removal of the N-Fmoc protecting group was carried out with 20% piperidine (Romil, Cambridge, UK) in N-methylpyrrolidone (NMP, M56 Chemicals, Runcorn, UK) followed by sequential washes with NMP.
- NMP N-methylpyrrolidone
- Ac-SEQ ID NO. 2 - NH 2 was synthesized using a semi-automated solid- phase approach (Labortec AG SP4000 peptide synthesiser) using the tricyclic amide linker resin (0.63 mmol/g loading). Amino acids were attached by Fmoc strategy on a 4 mmol scale using Fmoc chemistry with a single coupling time of 60 minutes. The completion of each coupling step was monitored using the Kaiser colour test. Recouplings were performed until a negative colour test was obtained.
- the resin and the amino acid derivatives, Fmoc-Ala-OH, Fmoc- Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Cys(Trt)-OH (positions 9 and 23), Fmoc-Cys(Acm)-OH (positions 2 and 21), Fmoc-Gln(Trt)- OH, Fmoc-Glu(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH and Fmoc-Tyr(tBu)-OH were purchased from Bachem AG, Bubendorf, Switzerland.
- Each amino acid was added sequentially to the growing peptide chain from the C- to the N- termini applying 2-(1 H-benzotriazol-1-yl)-1,1 ,3,3-tetramethyluronium tetrafluoroborate (TBTU, Severn Biotech Ltd, Kidderminster, UK) and N,N-diisopropylethylamine (DIEA, Fisher Chemicals, Loughborough, UK) as coupling reagents. Removal of the N- Fmoc protecting group was carried out with 20% piperidine (Romil, Cambridge, UK) in DMF, followed by sequential washes with DMF and propan-2-ol.
- 2-(1 H-benzotriazol-1-yl)-1,1 ,3,3-tetramethyluronium tetrafluoroborate TBTU, Severn Biotech Ltd, Kidderminster, UK
- DIEA N,N-diisopropylethylamine
- the peptides were cleaved from the resin with simultaneous deprotection using 82.5% TFA at room temperature for 3 hours in the presence of 5% thioanisole, 5% water, 2.5% ethanedithiol and 6% (w/v) phenol.
- the cleavage mixture was filtered and precipitated in ice-cold diethyl ether.
- the remaining resin was washed once with TFA, filtered, and combined with the previous fractions.
- the precipitates were stored at 4°C overnight and were collected by filtration, washed with ice-cold diethyl ether, and allowed to dry at room temperature.
- the crude peptides were dissolved in TFA/acetonitrile/water and lyophilized overnight (-50°C, 6 mbar). Characterization of crude peptides
- Peptides were characterised by reverse-phase HPLC (Gilson) using an analytical C-18 column (Vydac 218TP54, 250 x 4.6mm, 5 ⁇ m particle size, and 300 A pore size) and a linear AB gradient of 0-100% for B over 40 min at a flow rate of 1 mL/min, where eluent A was 0.1 % TFA/water and eluent B was 0.1 % TFA in 60% CH 3 CN/water. Mass was confirmed using MALDI-MS, and Ellman's colour test confirmed the presence of free sulphydryl groups where applicable. Production of bicyclic peptides
- the crude linear precursors were dissolved in the minimum TFA and diluted to 2 L/0.25 mmol with water.
- the first disulphide bridge was formed between unprotected Cys residues using K 3 Fe(CN) 6
- the peptide solution was adjusted to pH 7.5 with aqueous ammonium hydroxide.
- 0.01 M K 3 Fe(CN) 6 was added dropwise to excess, until a slight yellow colour remained.
- the completion of the reaction was confirmed by HPLC sampling after acidification.
- the pH of the solution was adjusted to 4 using 50% aqueous acetic acid.
- the crude reaction mixture was stirred with Bio-Rex 70 weak cation- exchange resin (BioRad, CA) overnight and packed into a glass column.
- the peptide was eluted using 50% aqueous acetic acid and detected by TLC using ninhydrin. Ninhydrin positive fractions were pooled and lyophilized. Crude material was purified via preparative reverse- phase HPLC. The purified fractions were collected, combined and lyophilised. The second disulphide bridge was formed via l 2 -oxidation between Cys(Acm) protected residues. A solution of the peptide (5 mg/ml) in 10% aqueous TFA was mixed vigorously with 8 equivalents of iodine. The course of the reaction was followed using HPLC sampling. At completion of the reaction (usually after 0.5 h), the excess iodine was quenched using 1 M ascorbic acid.
- the reaction mixture was diluted x 2 with eluent A, filtered through a 0.45 ⁇ m disposable filter and purified directly via preparative reverse-phase HPLC.
- the relevant fractions were collected, evaporated, lyophilized and stored at 4°C.
- Three peptides of the invention were obtained. They are referred to below as EG 3287 (bicyclic form of SEQ ID NO. 2), EG3307 (bicyclic form of Ac- SEQ ID NO. 2) and EG3315 (bicyclic form of Ac-SEQ ID NO. 2-NH 2 ).
- Full quality control was performed on all purified material.
- Peptides were shown to be greater than 95% pure by HPLC in two buffer systems (TFA and TEAP).
- KDR phosphorylation was determined by immunoblotting cell extracts with antibodies which recognise either KDR phosphorylated at Tyrosines 1054 and 1059 (purchased from Oncogene Research Products Inc.) or total KDR (purchased from Santa Cruz Inc.). Immunoreactive bands were visualised by chemiluminescence using horseradish peroxidase-conjugated anti-rabbit IgG and ECL reagent.
- Fig. 1 shows effects of cyclised VEGF Exon 7-derived peptides (100 ⁇ M) on 125 l- VEGF 165 binding to PAE/NP1 cells.
- it shows inhibition of VEGF radiolabelled ligand binding to porcine aortic endothelial cells (PAE) expressing only Neuropilin-1 (NP-1 ) by EG 3287, and no effect of a number of other related cyclic peptides.
- F9 and F10 refer to two fractions of the same peptide preparation.
- Fig. 2 shows specific, selective inhibition of 125 I-VEGF 165 binding to
- PAE/NP-1 cells but no effect on binding to cells expressing either only KDR (PAE/KDR) or Flt-1 (PAE/Flt-1), the other two main VEGF receptors.
- EG3287 also inhibited radiolabelled VEGF binding to human umbilical vein endothelial cells (HUVEC) which express NP-1 , KDR and Flt-1 (Fig.2), and inhibited VEGF- induced KDR phosphorylation (Fig. 3).
- Fig. 4 shows that peptide EG3287 also inhibited binding of radiolabelled VEGF to the breast carcinoma cell line MDA-MB-231 , that naturally expresses only NP-1 receptors for VEGF.
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003580381A JP2005531527A (en) | 2002-04-02 | 2003-03-28 | VEGF peptides and uses thereof |
IL16379903A IL163799A0 (en) | 2002-04-02 | 2003-03-28 | Vegf peptides and their use |
CA002481253A CA2481253A1 (en) | 2002-04-02 | 2003-03-28 | Vegf peptides and their use |
MXPA04009479A MXPA04009479A (en) | 2002-04-02 | 2003-03-28 | Vegf peptides and their use. |
US10/507,463 US20060166868A1 (en) | 2002-04-02 | 2003-03-28 | Vegf peptides and their use |
KR1020047015025A KR100641535B1 (en) | 2002-04-02 | 2003-03-28 | Vegf peptides and their use |
EP03745335A EP1490401B1 (en) | 2002-04-02 | 2003-03-28 | Vegf peptides and their use |
DE60313444T DE60313444T2 (en) | 2002-04-02 | 2003-03-28 | VEGF-PEPTIDES AND ITS USE |
AU2003226515A AU2003226515B2 (en) | 2002-04-02 | 2003-03-28 | VEGF peptides and their use |
NO20044105A NO20044105L (en) | 2002-04-02 | 2004-09-27 | VEGF peptides and their use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0207644.6 | 2002-04-02 | ||
GBGB0207644.6A GB0207644D0 (en) | 2002-04-02 | 2002-04-02 | Peptides and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003082918A1 true WO2003082918A1 (en) | 2003-10-09 |
Family
ID=9934136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2003/001375 WO2003082918A1 (en) | 2002-04-02 | 2003-03-28 | Vegf peptides and their use |
Country Status (17)
Country | Link |
---|---|
US (1) | US20060166868A1 (en) |
EP (1) | EP1490401B1 (en) |
JP (1) | JP2005531527A (en) |
KR (1) | KR100641535B1 (en) |
CN (1) | CN1642979A (en) |
AT (1) | ATE360644T1 (en) |
AU (1) | AU2003226515B2 (en) |
CA (1) | CA2481253A1 (en) |
DE (1) | DE60313444T2 (en) |
ES (1) | ES2283799T3 (en) |
GB (1) | GB0207644D0 (en) |
IL (1) | IL163799A0 (en) |
MX (1) | MXPA04009479A (en) |
NO (1) | NO20044105L (en) |
PL (1) | PL371546A1 (en) |
WO (1) | WO2003082918A1 (en) |
ZA (1) | ZA200406922B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005030242A1 (en) * | 2003-09-26 | 2005-04-07 | University Of Florida Research Foundation, Inc | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
WO2008040978A1 (en) * | 2006-10-04 | 2008-04-10 | Ark Therapeutics Ltd. | N-capped peptides with np-1 antagonist activity |
WO2008040979A1 (en) * | 2006-10-04 | 2008-04-10 | Ark Therapeutics Ltd. | Arginine derivatives with np-i antagonistic activity |
US7795213B2 (en) | 2001-12-13 | 2010-09-14 | Posco | Methods of contacting β amyloid protein with VEGF |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1904150B (en) * | 2006-08-01 | 2010-07-28 | 华东师范大学 | Human glucagon peptide/derivative and its solid phase chemical synthesis |
CN104774246B (en) * | 2014-03-21 | 2018-05-04 | 中山大学附属肿瘤医院 | NRP-1 specific tumours target polypeptide and its application |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993008473A1 (en) * | 1991-10-24 | 1993-04-29 | Beth Israel Hospital Association | Assay for malignant effusions |
WO1999029861A1 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Peptide antagonists of vascular endothelial growth factor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1248642A4 (en) * | 2000-01-18 | 2005-05-18 | Ludwig Inst Cancer Res | Vegf-d/vegf-c/vegf peptidomimetic inhibitor |
- 2002
- 2002-04-02 GB GBGB0207644.6A patent/GB0207644D0/en not_active Ceased
- 2003
- 2003-03-28 IL IL16379903A patent/IL163799A0/en unknown
- 2003-03-28 US US10/507,463 patent/US20060166868A1/en not_active Abandoned
- 2003-03-28 KR KR1020047015025A patent/KR100641535B1/en not_active IP Right Cessation
- 2003-03-28 EP EP03745335A patent/EP1490401B1/en not_active Expired - Lifetime
- 2003-03-28 AU AU2003226515A patent/AU2003226515B2/en not_active Ceased
- 2003-03-28 CA CA002481253A patent/CA2481253A1/en not_active Abandoned
- 2003-03-28 CN CNA038071134A patent/CN1642979A/en active Pending
- 2003-03-28 JP JP2003580381A patent/JP2005531527A/en not_active Ceased
- 2003-03-28 PL PL03371546A patent/PL371546A1/en not_active Application Discontinuation
- 2003-03-28 ES ES03745335T patent/ES2283799T3/en not_active Expired - Lifetime
- 2003-03-28 MX MXPA04009479A patent/MXPA04009479A/en active IP Right Grant
- 2003-03-28 WO PCT/GB2003/001375 patent/WO2003082918A1/en active IP Right Grant
- 2003-03-28 DE DE60313444T patent/DE60313444T2/en not_active Expired - Fee Related
- 2003-03-28 AT AT03745335T patent/ATE360644T1/en not_active IP Right Cessation
- 2004
- 2004-08-31 ZA ZA200406922A patent/ZA200406922B/en unknown
- 2004-09-27 NO NO20044105A patent/NO20044105L/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993008473A1 (en) * | 1991-10-24 | 1993-04-29 | Beth Israel Hospital Association | Assay for malignant effusions |
WO1999029861A1 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Peptide antagonists of vascular endothelial growth factor |
Non-Patent Citations (4)
Title |
---|
BAINBRIDGE JAMES W B ET AL: "A peptide encoded by exon 6 of VEGF (EG3306) inhibits VEGF-induced angiogenesis in vitro and ischaemic retinal neovascularisation in vivo.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 302, no. 4, 21 March 2003 (2003-03-21), pages 793 - 799, XP002245130, ISSN: 0006-291X * |
HAIYAN JIA ET AL: "PEPTIDES ENCODED BY EXON 6 OF VEGF INHIBIT ENDOTHELIAL CELL BIOLOGICAL RESPONSES AND ANGIOGENESIS INDUCED BY VEGF", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 283, no. 1, 2001, pages 164 - 173, XP002941058, ISSN: 0006-291X * |
SOKER S ET AL: "Characterization of novel Vascular Endothelial Growth Factor (VEGF) Receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 10, 8 March 1996 (1996-03-08), pages 5761 - 5767, XP002097905, ISSN: 0021-9258 * |
SOKER S ET AL: "Inhibition of Vascular Endothelial Growth Factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon7-encoded domain of VEGF165", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 50, 12 December 1997 (1997-12-12), pages 31582 - 31588, XP002098056, ISSN: 0021-9258 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7795213B2 (en) | 2001-12-13 | 2010-09-14 | Posco | Methods of contacting β amyloid protein with VEGF |
WO2005030242A1 (en) * | 2003-09-26 | 2005-04-07 | University Of Florida Research Foundation, Inc | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
WO2005030243A1 (en) * | 2003-09-26 | 2005-04-07 | Bristol Myers Squibb Company | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
US7148199B2 (en) | 2003-09-26 | 2006-12-12 | University Of Florida Research Foundation, Inc. | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
US7754692B2 (en) | 2003-09-26 | 2010-07-13 | University Of Florida Research Foundation, Inc. | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
WO2008040978A1 (en) * | 2006-10-04 | 2008-04-10 | Ark Therapeutics Ltd. | N-capped peptides with np-1 antagonist activity |
WO2008040979A1 (en) * | 2006-10-04 | 2008-04-10 | Ark Therapeutics Ltd. | Arginine derivatives with np-i antagonistic activity |
US8158789B2 (en) | 2006-10-04 | 2012-04-17 | Ark Therapeutics Group Ltd. | Arginine derivatives with NP-I antagonistic activity |
US8227606B2 (en) | 2006-10-04 | 2012-07-24 | Ark Therapeutics, Ltd. | Arginine derivatives with NP-1 antagonistic activity |
Also Published As
Publication number | Publication date |
---|---|
EP1490401A1 (en) | 2004-12-29 |
JP2005531527A (en) | 2005-10-20 |
AU2003226515A1 (en) | 2003-10-13 |
EP1490401B1 (en) | 2007-04-25 |
CN1642979A (en) | 2005-07-20 |
CA2481253A1 (en) | 2003-10-09 |
NO20044105L (en) | 2004-10-27 |
GB0207644D0 (en) | 2002-05-15 |
IL163799A0 (en) | 2005-12-18 |
ZA200406922B (en) | 2006-06-28 |
DE60313444D1 (en) | 2007-06-06 |
AU2003226515B2 (en) | 2006-06-08 |
ATE360644T1 (en) | 2007-05-15 |
US20060166868A1 (en) | 2006-07-27 |
MXPA04009479A (en) | 2005-01-25 |
KR100641535B1 (en) | 2006-10-31 |
ES2283799T3 (en) | 2007-11-01 |
PL371546A1 (en) | 2005-06-27 |
DE60313444T2 (en) | 2007-08-30 |
KR20040099356A (en) | 2004-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101399678B1 (en) | Dimerized peptide | |
US5767239A (en) | Process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same | |
JP2634323B2 (en) | Plasmid containing DNA encoding amino acid sequence of TCF-II, transformed cell, and method for producing bioactive substance using the same | |
DK2437773T3 (en) | PROCEDURE FOR IMPROVING PHAGOCYTOSIS OF PHOSPHATIDYLSERINE-EXPOSING CELLS | |
KR20110125235A (en) | Cytotoxic conjugates having neuropeptide y receptor binding compound | |
CN113330024A (en) | Method for preparing GIP/GLP1 dual agonist | |
AU2020334993B2 (en) | Methods of making incretin analogs | |
EP1490401B1 (en) | Vegf peptides and their use | |
AU2002210713B2 (en) | Vegf peptides and their use for inhibiting angiogenesis | |
AU2002210713A1 (en) | VEGF peptides and their use for inhibiting angiogenesis | |
US20110212890A1 (en) | Metastin derivative and use thereof | |
CN107325187B (en) | Polypeptide with CXCR4 protein agonistic activity and application and pharmaceutical composition thereof | |
KR102166543B1 (en) | Composition and Method for Inhibiting Keloid | |
MXPA01010302A (en) | Polypeptides derived from endostatin exhibiting antiangiogenic activity. | |
CN116731113A (en) | Polypeptide compound for SORT1 and drug conjugate thereof | |
KR20210118857A (en) | Novel intermediates used for bioactive polypeptides and methods for their preparation | |
WO2008040978A1 (en) | N-capped peptides with np-1 antagonist activity | |
CN110655583A (en) | Novel Bcl10 polymerization inhibitor and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states | Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents | Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase | Ref document number: 2003745335 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase | Ref document number: 163799 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase | Ref document number: 2004/06922 Country of ref document: ZA Ref document number: 200406922 Country of ref document: ZA |
|
ENP | Entry into the national phase | Ref document number: 2006166868 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase | Ref document number: 10507463 Country of ref document: US Ref document number: 2003226515 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase | Ref document number: 1020047015025 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase | Ref document number: 2854/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase | Ref document number: 20038071134 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase | Ref document number: PA/a/2004/009479 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase | Ref document number: 2481253 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase | Ref document number: 2003580381 Country of ref document: JP |
|
WWP | Wipo information: published in national office | Ref document number: 1020047015025 Country of ref document: KR |
|
WWP | Wipo information: published in national office | Ref document number: 2003745335 Country of ref document: EP |
|
WWP | Wipo information: published in national office | Ref document number: 10507463 Country of ref document: US |
|
WWG | Wipo information: grant in national office | Ref document number: 2003745335 Country of ref document: EP |